PrometDobitKGVKUVEBITDividendaAkcijeKapitalizacija tržištaDugovanjeObavezeKapital društvaAAQSzaposleniROEROAROCE
Prothena Corporation Akcija

Prothena Corporation AAQS 2024

Prothena Corporation AAQS

6

Тикер

PRTA

ISIN

IE00B91XRN20

WKN

A1KAVV

Prothena Corporation ima trenutni AAQS od 6. Visok AAQS može se smatrati pozitivnim pokazateljem da se preduzeće uspešno razvija. Investitori mogu očekivati da je kompanija na dobrom putu da ostvari dobit. S druge strane, važno je posmatrati AAQS deonice Prothena Corporation u poređenju sa ostvarenom dobiti i drugim preduzećima iste branše. Visok AAQS nije apsolutna garancija za pozitivnu budućnost. Samo tako se može dobiti kompletna slika o performansama kompanije. Da bi se bolje procenio razvoj preduzeća, važno je posmatrati AAQS u poređenju sa drugim kompanijama iste branše. Generalno, investitori bi uvek trebali da posmatraju AAQS kompanije u kontekstu sa drugim finansijskim pokazateljima kao što su dobit, EBIT, Cash Flow i drugi, kako bi doneli obrazovane odluke o investiranju.

Prothena Corporation Aktienanalyse

Šta radi Prothena Corporation?

Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Često postavljana pitanja o Prothena Corporation akciji

Plansovi za štednju u akcijama nude atraktivnu mogućnost za investitore da dugoročno izgrade bogatstvo. Jedna od glavnih prednosti je takozvani efekat prosečne cene: investiranjem redovnog fiksnog iznosa u akcije ili fondove akcija, automatski se kupuju više deonica kada su cene niske i manje kada su visoke. To može dovesti do povoljnijeg prosečnog cena po deonici tokom vremena. Pored toga, plansovi za štednju u akcijama omogućuju čak i malim ulagačima pristup skupim akcijama, pošto je moguće učestvovati već sa malim iznosima. Redovno investiranje takođe podstiče disciplinovanu strategiju ulaganja i pomaže da se izbegnu emocionalne odluke, kao što su impulsivno kupovanje ili prodaja. Osim toga, investitori profitiraju od potencijalnog povećanja vrednosti akcija kao i od isplata dividendi, koje se mogu reinvestirati, što pojačava efekat kamate na kamatu i time rast investiranog kapitala.

Andere Kennzahlen von Prothena Corporation

Naša analiza akcija za akciju Prothena Corporation Promet uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije Prothena Corporation Promet. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: